|Bid||59.40 x 800|
|Ask||59.43 x 2200|
|Day's Range||59.23 - 59.46|
|52 Week Range||54.41 - 72.32|
|PE Ratio (TTM)||N/A|
|Beta (3Y Monthly)||0.00|
|Expense Ratio (net)||0.32%|
E*TRADE Financial Corporation today announced it has surpassed 250 commission-free ETFs with the addition of 46 ETFs from six providers to its Commission-Free ETF Pr
Retirees are often on the hunt for income, and foreign stocks and bonds tantalize by offering yields that are often higher than comparable payouts available on the home front. Foreign bonds from developed markets yield less than U.S. bonds today, but emerging-markets bonds, especially those denominated in local currencies, offer positively robust yields of 5% or 6%. When foreign currencies gain in value relative to the dollar, investors who own foreign-currency-denominated stocks and bonds win.
At a time when U.S. interest rates are rising, income investors may want to consider ex-US dividend stocks and the related exchange traded funds. One idea on that front is the Vanguard International High ...
Markets outside the United States, both developed and emerging, offer income investors compelling opportunities to find dividend growth and higher yields than equivalent U.S. stocks. Exchange-traded funds ...
Ex-U.S. developed market dividend payers often feature larger yields than their U.S. counterparts, an assertion proven by comparing large- and mega-cap dividend stocks from familiar dividend sectors such ...
In 3Q17, GlaxoSmithKline (GSK) reported revenues close to 2.0 billion pounds from the sale of its consumer healthcare products, which is year-over-year (or YoY) growth of 5% on a reported basis and 2% on a constant exchange rate (or CER). GlaxoSmithKline witnessed sales worth 429 million pounds for its consumer healthcare franchise in the US market in 3Q17, which is YoY growth of 1% on a reported basis but a drop of 1% on a CER basis.
On November 4, 2015, the U.S. Food and Drug Administration (or FDA) approved GlaxoSmithKline’s (GSK) interleukin-5 antagonist monoclonal antibody, Nucala, as maintenance therapy for severe eosinophilic asthma patients who have been previously treated with other asthma medications and are 12 years or older. On December 12, 2017, the FDA expanded Nucala’s label and approved the therapy for patients suffering from eosinophilic granulomatosis with polyangiitis (or EGPA).